Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + bendamustine + rituximab combination therapy
- Development stage
- Phase 3
- Lead developer
- BeiGene
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of zanubrutinib, bendamustine, and rituximab (often abbreviated as ZBR) is a therapeutic regimen being investigated for the treatment of certain blood cancers. This combination brings together a Bruton tyrosine kinase (BTK) inhibitor (zanubrutinib) with a chemotherapy agent (bendamustine) and an anti-CD20 monoclonal antibody (rituximab). The ZBR regimen has shown promising results in clinical trials, particularly for Waldenström macroglobulinemia (WM) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In newly diagnosed symptomatic WM patients, the ZBR regimen achieved significant deep remission rates with manageable adverse events. In clinical trials, the combination is typically administered as follows: - Zanubrutinib: 160 mg twice daily, orally, for up to 12 months - Bendamustine: 70 mg/m² intravenously on days 1 and 2 of each cycle - Rituximab: 375 mg/m² intravenously on day 1 of each cycle Treatment is usually administered for 6 cycles.
- Other names
- ZBR
02
Targets
Beyond the preview
Go deeper on zanubrutinib + bendamustine + rituximab combination therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + bendamustine + rituximab combination therapy.